Moreover, other investigators have shown that mechanistic models of interleukin-21 (IL-21) therapy schedules based on tumor mass and antigenic properties can predict growth patterns of multiple tumor types in patients receiving personalized doses of IL-21 (de Pillis et al., 2005). This evidence concerns the gene IL21 and neoplasm.